HOME >> BIOLOGY >> NEWS
September/October 2004 Annals of Family Medicine tip sheet

114 vs. 149). They also found significant differences in the number of arrests for controlled substance or liquor violations (0 vs. 8). The authors suggest that these compelling findings point to the efficacy of brief counseling one of the most important therapeutic modalities used by physicians. With alcohol-related mortality still the most common cause of death in young adults, the authors recommend primary care providers make counseling for high-risk drinking in young adults a critical priority.
Brief Physician Advise for High-Risk Drinking Among Young Adults
By Paul M. Grossberg, M.D., et al

Family Physicians Care for Many Problems, Record Fewer on Bill
Visits to family physicians frequently involve the concurrent care of multiple problems that billing data do not adequately reflect. Analyzing physician logs from 572 patient encounters, researchers found that physicians report managing an average of 3.05 problems per encounter but record only 2.82 in the chart and 1.97 on the bill. For all patients, 37 percent of encounters logged addressed more than three problems, and 18 percent addressed more than four. For patients older than 65, physicians recorded an average of 3.88 problems per visit; for diabetic patients, they recorded an average of 4.6. The authors posit that these findings suggest a mismatch between family medicine and current approaches to quality assessment, guideline implementation, education, research, administration and funding. Future work in these areas, they assert, needs to address the primary care physician's task of prioritizing and integrating care for multiple problems concurrently.
How Many Problems Do Family Physicians Manage at Each Encounter? A WReN Study
By John W. Beasley, M.D., et al

Rethinking How Provider Continuity Is Defined: A Case for Including Patients and Informal Caregivers
In a thought-provoking essay, Stephen Buetow, M.D. calls for a fun
'"/>

Contact: Angela Lower
alower@aafp.org
913-906-6253
American Academy of Family Physicians
5-Oct-2004


Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology news :

1. Sept/Oct 2005 Annals of Family Medicine tip sheet
2. Annals of Internal Medicine tip sheet for Oct. 5, 2004
3. Family members with MS likely to share onset age, but not disease severity
4. Straus Family Creamery receives award for ecological practices
5. Family of life-extending genes discovered
6. Family trees of ancient bacteria reveal evolutionary moves
7. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
8. Journal of Nuclear Medicines impact grows, remains consistently high over past 5 years
9. University of Pittsburgh School of Medicine researchers develop off-the-shelf vascular grafts
10. Depiction of findings selected as 2007 Image of the Year by Society for Nuclear Medicine
11. 454 Life Sciences and Baylor College of Medicine complete sequencing of DNA pioneer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: September October Annals Family Medicine tip sheet

(Date:5/21/2013)... at Chicago College of Medicine will study gender differences in ... energy source -- and how changes in fat metabolism play ... 4-year grant from the National Heart, Lung and Blood Institute. ... for energy. These changes may play a major role in ... and women, says E. Douglas Lewandowski, director of the UIC ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... is known about the effect of physical education (PE) ... University finds that increasing the amount of time that ... of obesity. , The study represents some of the ... youth obesity, and is forthcoming in the Journal ... of the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 As ... a strong push within the industry to deliver ... Manufacturing Organizations and pharma companies often means turning ... , Microtablets, developed in collaboration with Sensidose AB ... outsourcing can bring products to market sooner. The ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: